Metronomic chemotherapy in head and neck cancer.
Head neck cancer (HNC) is generally treated with a multimodality approach. Loco-regional-distant control is often worst, due to the advantage stage disease at diagnosis and the optimal treatment option remains an unresolved issue. Metronomic chemotherapy (MCHT) is an emerging therapeutic option in clinical oncology and it may prove useful in HNC patients.
Department of Radiotherapy, Policlinico Umberto I "Sapienza" University of Rome, Viale Regina Elena 326, 00161, Rome, Italy. Electronic address: fradefelice@hotmail.it.
Francesca
F
De Felice
Department of Radiotherapy, Policlinico Umberto I "Sapienza" University of Rome, Viale Regina Elena 326, 00161, Rome, Italy.
Ilaria
I
Benevento
Department of Gynecology, Obstetrics and Urological Sciences, "Sapienza" University of Rome, Viale Regina Elena 326, 00161, Rome, Italy.
Angela
A
Musella
Department of Radiotherapy, Policlinico Umberto I "Sapienza" University of Rome, Viale Regina Elena 326, 00161, Rome, Italy.
Daniela
D
Musio
Department of Radiotherapy, Policlinico Umberto I "Sapienza" University of Rome, Viale Regina Elena 326, 00161, Rome, Italy; Spencer-Lorillard Foundation, Viale Regina Elena 262, Rome, Italy.
Vincenzo
V
Tombolini
D059250:Administration, Metronomic; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D019317:Evidence-Based Medicine; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000970:Antineoplastic Agents
Head neck cancer; Low dose; Metronomic chemotherapy; Recurrence; Survival; Treatment